BJMO - volume 15, issue 3, may 2021
M. De Praeter MD
Although prognosis of non-small cell lung carcinoma (NSCLC) patients with brain metastases (BMs) has improved over the last years, the overall survival remains poor. Indications for surgical resection of a single BM have been well defined in the literature: Limited and or controlled systemic disease, Karnofsky performance scale ≥70, solitary lesion larger than 3 cm, non-eloquent area of the brain and unclear pathological diagnosis. However, recent advances in surgical technique and intraoperative technologies have facilitated surgery, including surgery for multiple lesions and lesions in eloquent brain areas.1–4 With the advance of molecularly targeted therapy, selection of patients who qualify for surgery of their BMs has become even more complex.5 The purpose of this review is to determine the indications and timing of surgery for brain metastases in NSCLC.
BELG J MED ONCOL 2021;15(3):104-11
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
